Back to Hematology
Hematologyv2010Evidence-Based

Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival

Predicts transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
duval cibmtr score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score = disease_group_points + cytogenetics_points + hla_match_points + circulating_blasts_points + karnofsky_points. Total score ranges from 0-5 points with lower scores indicating better prognosis.

Clinical Pearls & Practice Notes

  • The Duval/CIBMTR Score was developed from analysis of 1,673 AML patients undergoing allogeneic HSCT.
  • The score is specifically designed for patients with active AML disease at time of conditioning.
  • Only busulfan and TBI-based myeloablative conditioning regimens were studied in the original validation.
  • Reduced-intensity conditioning, syngeneic, and cord blood transplants were excluded from the original study.
  • First complete remission (CR) duration <6 months indicates higher risk compared to longer CR duration.
  • Primary induction failure refers to failure to achieve complete remission after initial induction chemotherapy.
  • Poor cytogenetics includes complex karyotype (≥3 abnormalities), -5/del(5q), -7/del(7q), inv(3q), t(6;9), t(9;22), 11q23 abnormalities.
  • Good cytogenetics includes t(8;21), inv(16)/t(16;16), t(15;17). Intermediate includes normal karyotype and other abnormalities.
  • HLA identical sibling donors provide the best outcomes, followed by well-matched unrelated donors.
  • Presence of circulating blasts at transplant indicates active disease and worse prognosis.
  • Karnofsky Performance Status <90 indicates functional impairment that negatively impacts outcomes.
  • The score helps guide transplant decision-making and patient counseling regarding expected outcomes.
  • Post-transplant complications including graft-versus-host disease may be higher in poor prognostic groups.
  • Score should be used in conjunction with other clinical factors and institutional experience.
  • Regular reassessment of disease status and performance status is recommended during pre-transplant evaluation.
  • The score has been validated in multiple international cohorts and remains relevant for contemporary practice.

Evidence & Literature Citations

  1. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730-8. doi: 10.1200/JCO.2010.28.8852.
  2. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, et al. A phase 3 randomized study of 5-azacytidine vs physicians' choice as maintenance therapy for patients with AML in first remission after intensive chemotherapy ineligible for stem cell transplantation. Blood. 2013;121(24):4906-14.
  3. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-1.
  4. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-90. doi: 10.1038/nrclinonc.2012.150.

Score Interpretation Ranges

Score 00 – 0 pts

Excellent prognosis

Score 11 – 1 pts

Good prognosis

Score 22 – 2 pts

Intermediate prognosis

Score ≥33 – 5 pts

Poor prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.